S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
ETR:MOR

MorphoSys AG (MOR.F) Stock Forecast, Price & News

€93.02
+0.88 (+0.96 %)
(As of 01/18/2021 12:00 AM ET)
Add
Compare
Today's Range
€90.84
Now: €93.02
€93.64
50-Day Range
€89.88
MA: €93.61
€99.30
52-Week Range
€65.25
Now: €93.02
€125.20
Volume117,777 shs
Average Volume153,687 shs
Market Capitalization$3.05 billion
P/E Ratio47.03
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys AG (MOR.F) logo

MarketRank

Overall MarketRank

1.40 out of 5 stars

Analyst Opinion: 4.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-89-899270
Employees640

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$302.73 million
Cash Flow€24.35 per share
Book Value€18.27 per share

Profitability

Miscellaneous

Market Cap$3.05 billion
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
€93.02
+0.88 (+0.96 %)
(As of 01/18/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys AG (MOR.F) (ETR:MOR) Frequently Asked Questions

How has MorphoSys AG (MOR.F)'s stock been impacted by COVID-19?

MorphoSys AG (MOR.F)'s stock was trading at €91.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MOR stock has increased by 2.2% and is now trading at €93.02.
View which stocks have been most impacted by COVID-19
.

Is MorphoSys AG (MOR.F) a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys AG (MOR.F) in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MorphoSys AG (MOR.F) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys AG (MOR.F)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MorphoSys AG (MOR.F)?

Wall Street analysts have given MorphoSys AG (MOR.F) a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MorphoSys AG (MOR.F) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MorphoSys AG (MOR.F)'s next earnings date?

MorphoSys AG (MOR.F) is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for MorphoSys AG (MOR.F)
.

What price target have analysts set for MOR?

9 Wall Street analysts have issued 1 year price targets for MorphoSys AG (MOR.F)'s shares. Their forecasts range from €90.00 to €140.00. On average, they expect MorphoSys AG (MOR.F)'s stock price to reach €118.67 in the next year. This suggests a possible upside of 27.6% from the stock's current price.
View analysts' price targets for MorphoSys AG (MOR.F)
or view Wall Street analyst' top-rated stocks.

Who are some of MorphoSys AG (MOR.F)'s key competitors?

What other stocks do shareholders of MorphoSys AG (MOR.F) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys AG (MOR.F) investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), SolarEdge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), MercadoLibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA).

Who are MorphoSys AG (MOR.F)'s key executives?

MorphoSys AG (MOR.F)'s management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 56, Pay $2.03M)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 59, Pay $1.37M)
  • Mr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 49)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn, Sr. VP & Head of Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 51)
  • Mr. Thomas Biegi, VP & Head of Corp. Communications

What is MorphoSys AG (MOR.F)'s stock symbol?

MorphoSys AG (MOR.F) trades on the ETR under the ticker symbol "MOR."

What is MorphoSys AG (MOR.F)'s stock price today?

One share of MOR stock can currently be purchased for approximately €93.02.

How big of a company is MorphoSys AG (MOR.F)?

MorphoSys AG (MOR.F) has a market capitalization of $3.05 billion and generates $302.73 million in revenue each year. MorphoSys AG (MOR.F) employs 640 workers across the globe.

What is MorphoSys AG (MOR.F)'s official website?

The official website for MorphoSys AG (MOR.F) is www.morphosys.de.

How can I contact MorphoSys AG (MOR.F)?

MorphoSys AG (MOR.F)'s mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.